117 related articles for article (PubMed ID: 26593977)
1. Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.
Khan H; Paeshuyse J; Murad S; Neyts J
Antiviral Res; 2016 Jan; 125():43-5. PubMed ID: 26593977
[TBL] [Abstract][Full Text] [Related]
2. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
3. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
4. SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A
Oyero OG; Toyama M; Mitsuhiro N; Onifade AA; Hidaka A; Okamoto M; Baba M
Afr J Tradit Complement Altern Med; 2016; 13(6):144-148. PubMed ID: 28480371
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
6. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG
Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814
[TBL] [Abstract][Full Text] [Related]
7. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
8. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.
Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE
Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631
[TBL] [Abstract][Full Text] [Related]
9. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
Li S; Kodama EN; Inoue Y; Tani H; Matsuura Y; Zhang J; Tanaka T; Hattori T
Antivir Chem Chemother; 2010 Aug; 20(6):239-48. PubMed ID: 20710064
[TBL] [Abstract][Full Text] [Related]
10. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
Koutsoudakis G; Romero-Brey I; Berger C; Pérez-Vilaró G; Monteiro Perin P; Vondran FW; Kalesse M; Harmrolfs K; Müller R; Martinez JP; Pietschmann T; Bartenschlager R; Brönstrup M; Meyerhans A; Díez J
J Hepatol; 2015 Oct; 63(4):813-21. PubMed ID: 26070407
[TBL] [Abstract][Full Text] [Related]
11. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
12. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
13. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
Calland N; Sahuc ME; Belouzard S; Pène V; Bonnafous P; Mesalam AA; Deloison G; Descamps V; Sahpaz S; Wychowski C; Lambert O; Brodin P; Duverlie G; Meuleman P; Rosenberg AR; Dubuisson J; Rouillé Y; Séron K
J Virol; 2015 Oct; 89(19):10053-63. PubMed ID: 26202241
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.
Kanda T; Steele R; Ray R; Ray RB
J Virol; 2007 Jan; 81(2):669-76. PubMed ID: 17079316
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
16. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
Korba BE; Montero AB; Farrar K; Gaye K; Mukerjee S; Ayers MS; Rossignol JF
Antiviral Res; 2008 Jan; 77(1):56-63. PubMed ID: 17888524
[TBL] [Abstract][Full Text] [Related]
17. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV.
Meissner EG
Liver Int; 2015 Feb; 35(2):295-6. PubMed ID: 25424883
[No Abstract] [Full Text] [Related]
18. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
[TBL] [Abstract][Full Text] [Related]
19. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
[TBL] [Abstract][Full Text] [Related]
20. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
Zhao Q; Xia N
Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
